The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

The addition of 64/67Cu-SAR-trastuzumab complements Clarity’s broader pipeline, which includes SAR-Bombesin, SARTATE, and SAR-bisPSMA. The company plans to conduct a Phase 1/2a theranostic study to ...

Puma Biotechnology will issue its 4Q and full year 2024 results on Feb. 27 and follow with a conference call at 1:30 p.m.

Clarity about the superiority of the two trastuzumab-containing ADCs in HER2 ... and Roche Products Ltd. Co-authors reported multiple relationships with industry.

trastuzumab plus an additional HER2-directed ... Ph.D., of Nucleus Global, an Inizio Company, for medical writing assistance with an earlier version of the manuscript.

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...

At seven-years follow up, invasive disease-free survival was 80.8% with adjuvant T-DM1 and 67.1% with adjuvant trastuzumab alone. Overall survival was 89.1% with T-DM1 and 84.4% with trastuzumab ...

and co-authors performed a meta-analysis of mitochondria-related gene expression data in trastuzumab-treated cardiomyocytes. They analyzed 1,243 genes and observed 69 up-regulated genes after ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. New England Journal of Medicine , 2025; 392 (3): 249 DOI: 10.1056/NEJMoa2406070 Cite This Page : ...